ImageILD (EORTC 1658-IG)
Research type
Research Study
Full title
Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD)
IRAS ID
247439
Contact name
Julie Coupain
Contact email
Sponsor organisation
European Organisation for the Research and Treatment of Cancer (EORTC)
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 2 months, 15 days
Research summary
Anti-cancer drugs are given to treat cancer, but can also have side effects, including damage to the lungs. An abnormal healing response can lead to lung inflammation and eventually scarring, making it difficult for oxygen to pass into the bloodstream. These abnormalities are called ‘drug-induced interstitial lung disease (DIILD)’. Over four hundred drugs are known to cause DIILD.
Currently, the routine test to diagnose DIILD is a CT (computed tomography) scan of the chest. Results are interpreted with information about symptoms and drug history. CT images give useful information, but results are non-specific and so it isn’t always possible to make a reliable diagnosis of DIILD or to determine its severity. The purpose of this study is to test a standardised CT scoring system for the diagnosis and assessment of DIILD. If the scoring system is successful it may be adopted as a more reliable method of diagnosing DIILD.
The study will recruit adult patients who develop suspected DIILD while on cancer treatment. They will have a series of CT scans and routine lung function tests (breathing tests). CT scans will be centrally reviewed and scored by the study radiologists and results compared with lung function tests to qualify the CT scoring method as a new diagnostic test. Patients will also undergo history and physical examinations, and complete study questionnaires. DIILD will be managed at the discretion of the treating physicians, however details and clinical outcomes will be collected by the study team along with results of clinical examinations, blood tests and other investigations.
This study will take place in NHS sites in the UK as part of a wider international study. The study is sponsored and coordinated by the EORTC (European Organisation for Research and Treatment of Cancer).
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0506
Date of REC Opinion
13 Sep 2018
REC opinion
Further Information Favourable Opinion